Skip to content

Xeris Biopharma Holdings, Inc.

XERS· NasdaqCore metricsCIK 1867096

Pharmaceutical preparations552 peers

Last sale
Nov 12, 2026 · +0.85%
Market cap
$3.04B
182.7M shares
Filings
346
$107.23M
Q3 2026+43.7% FY25 yoy
$11.29M
Q3 2026N/M FY25 yoy
$16.92M
Q3 2026N/M FY25 yoy
-$96.62M
FY 2021derivedN/M FY21 yoy
$0.06
Q3 2026N/M FY25 yoy
$131.08M
Q3 2026+55.0% FY25 yoy
$3.04B
—
8.3×
62.4×
—
—

Twelve months to Sep 30, 2026 · derived

Price

$16.65+123.79%+$9.21past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$291.85MFY 2025
$291.85M0FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$291,845,000reported
FY 20242024-12-31$203,070,000reported
FY 20232023-12-31$163,914,000reported
FY 20222022-12-31$110,248,000reported
FY 20212021-12-31$49,590,000 revisedreported
FY 20202020-12-31$20,155,000reported

Segments

Products
Revenue by Products, FY2021 to FY2025FY2021Gvoke · FY2021 · $38.92MKeveyis · FY2021 · $10.36MRoyalty, contract and other revenue · FY2021 · $310.00KFY2022Recorlev · FY2022 · $7.43MGvoke · FY2022 · $52.53MKeveyis · FY2022 · $49.31MRoyalty, contract and other revenue · FY2022 · $985.00KFY2023Recorlev · FY2023 · $29.55MGvoke · FY2023 · $67.05MKeveyis · FY2023 · $56.77MRoyalty, contract and other revenue · FY2023 · $10.55MFY2024Recorlev · FY2024 · $64.28MGvoke · FY2024 · $82.83MKeveyis · FY2024 · $49.53MRoyalty, contract and other revenue · FY2024 · $6.43MFY2025Recorlev · FY2025 · $139.28MGvoke · FY2025 · $94.11MKeveyis · FY2025 · $47.65MRoyalty, contract and other revenue · FY2025 · $8.84MOther product revenue · FY2025 · $1.96M
LineFY2025ShareChange
Recorlev$139.28M48%+116.7%
Gvoke$94.11M32%+13.6%
Keveyis$47.65M16%−3.8%
Royalty, contract and other revenue$8.84M3.0%+37.4%
Other product revenue$1.96M0.7%—
Total$291.85M

From the 10-K filed Mar 2, 2026XERS

Pharmaceutical preparations

Xeris Biopharma Holdings, Inc. is the 70th largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Xeris Biopharma Holdings, Inc. · CIK 1867096 · Engraved from SEC EDGAR